Europe’s medicines regulator on Friday recommended approving the use of Moderna’s COVID-19 vaccine in 12- to 17-year olds. This makes it the second jab approved for use among adolescents in Europe.
The use of the vaccine, branded Spikevax, will be the same in adolescents as in people above 18 years, the European Medicines Agency (EMA) said, adding the vaccine produced a comparable antibody response to that seen in 18- to 25-year olds.
The vaccine will be given in two injections. The time period between the first and second dose would be four weeks.
The EMA said that the effects of the Moderna jab were studied among 3,732 children aged 12-17 years.
The Moderna jab employs the same mRNA technology as Pfizer/BioNTech, using genetic material to deliver instructions to human cells to create coronavirus spike proteins. It thereby trains an immune response without exposing the host to a real infection.
The use of the vaccine, branded Spikevax, will be the same in adolescents as in people above 18 years, the European Medicines Agency (EMA) said, adding the vaccine produced a comparable antibody response to that seen in 18- to 25-year olds.
The vaccine will be given in two injections. The time period between the first and second dose would be four weeks.
The EMA said that the effects of the Moderna jab were studied among 3,732 children aged 12-17 years.
The Moderna jab employs the same mRNA technology as Pfizer/BioNTech, using genetic material to deliver instructions to human cells to create coronavirus spike proteins. It thereby trains an immune response without exposing the host to a real infection.
